CorMedix Inc.'s DefenCath shows considerable promise in reducing catheter-related bloodstream infections. Click here for this ...

Needham analyst Serge Belanger maintained a Buy rating on Cormedix (CRMD – Research Report) today and set a price target of $18.00.Stay Ahead ...

Shares of CorMedix were higher after the company reported preliminary fourth-quarter results that beat the company's and analysts' expectations. The company's stock increased 21% to $9.63 in morning ...

A final clinical study protocol for DefenCath in Total Parenteral Nutrition (TPN) was submitted to FDA in Q4, and study enrollment is expected to begin in H1 2025. The Company also expects patient ...

The aXess EU pivotal trial is a prospective study investigating the patency, safety, and performance of aXess in adult patients with end-stage renal disease requiring vascular access to start or ...

After professing a hearty appetite for tuck-in M&A last year and signing a string of smaller deals, Stryker is now opening ...

The Tripura Human Rights Commission (THRC) has issued a notice to ILS Hospital in Agartala, seeking its response to ...

BrainChild Bio, Inc., a clinical-stage biotechnology company developing CAR T-cell therapies to treat tumors in the central nervous system (CNS), today announced the clinical development plan to ...

Xeltis announced today that it completed enrollment in an EU pivotal trial for aXess, its restorative vascular access conduit ...

Q4 2024 Unaudited Net Revenue of Approximately $31mm ? ? FY 2024 Unaudited Net Revenue of Approximately $43mm ? ? Expects Q4 Adjusted EBITDA to Exceed $12mm ? BERKELEY HEIGHTS, N.J., Jan. 07, 2025 ...

Hunter Custer, an area entrepreneur and local business owner, is facing a life threatening prognosis after being rushed to an Eau Claire emergency medical center on Dec. 23.